TY - JOUR
T1 - Current and future antiviral strategies to tackle gastrointestinal viral infections
AU - Santos-Ferreira, Nanci
AU - Van Dycke, Jana
AU - Neyts, Johan
AU - Rocha-Pereira, Joana
N1 - Funding Information:
Funding: This work has received funding from the European Union Horizon 2020 research and innovation program, OrganoVIR, under the Marie Skłodowska-Curie grant agreement no. 812673 and from the GUTvibrations European Consortium grant agreement no. 953201.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/8
Y1 - 2021/8
N2 - Acute gastroenteritis caused by virus has a major impact on public health worldwide in terms of morbidity, mortality, and economic burden. The main culprits are rotaviruses, noroviruses, sapoviruses, astroviruses, and enteric adenoviruses. Currently, there are no antiviral drugs available for the prevention or treatment of viral gastroenteritis. Here, we describe the antivirals that were identified as having in vitro and/or in vivo activity against these viruses, originating from in silico design or library screening, natural sources or being repurposed drugs. We also highlight recent advances in model systems available for this (hard to cultivate) group of viruses, such as organoid technologies, and that will facilitate antiviral studies as well as fill some of current knowledge gaps that hamper the development of highly efficient therapies against gastroenteric viruses.
AB - Acute gastroenteritis caused by virus has a major impact on public health worldwide in terms of morbidity, mortality, and economic burden. The main culprits are rotaviruses, noroviruses, sapoviruses, astroviruses, and enteric adenoviruses. Currently, there are no antiviral drugs available for the prevention or treatment of viral gastroenteritis. Here, we describe the antivirals that were identified as having in vitro and/or in vivo activity against these viruses, originating from in silico design or library screening, natural sources or being repurposed drugs. We also highlight recent advances in model systems available for this (hard to cultivate) group of viruses, such as organoid technologies, and that will facilitate antiviral studies as well as fill some of current knowledge gaps that hamper the development of highly efficient therapies against gastroenteric viruses.
KW - Adenovirus
KW - Astrovirus
KW - Enteroids
KW - In vitro
KW - In vivo
KW - Norovirus
KW - Rotavirus
KW - Sapovirus
KW - Viral gastroenteritis
UR - http://www.scopus.com/inward/record.url?scp=85111107596&partnerID=8YFLogxK
U2 - 10.3390/microorganisms9081599
DO - 10.3390/microorganisms9081599
M3 - Review article
C2 - 34442677
AN - SCOPUS:85111107596
SN - 2076-2607
VL - 9
JO - Microorganisms
JF - Microorganisms
IS - 8
M1 - 1599
ER -
